Nuvation Bio reported strong momentum in its first full quarter post-IBTROZI FDA approval, with 204 new patient starts and continued positive feedback from the medical community regarding its efficacy and safety profile.

• IBTROZI achieved 204 new patient starts during Q3 2025, averaging over 15 per week, indicating robust market acceptance.
• The median duration of response for TKI-naive patients has increased to 50 months, supporting the drug's competitive positioning as a potential new standard of care.
• Recent clinical data showcased an impressive 66% intracranial response rate in patients with brain metastases, highlighting IBTROZI's unique efficacy in a critical patient subgroup.
• Nuvation Bio plans to submit a supplemental NDA for a label update based on the latest data, aiming to enhance product positioning further.
• The company continues to differentiate IBTROZI from competitors by emphasizing its safety and efficacy in real-world clinical settings.